Home >> People >> Faculty
WANG Yuexiang


Professor, Principal Investigator

Laboratory of Cancer Progression and Translational Medicine

Email: yxwang76@sibs.ac.cn

Tel: 86-21-54923278

Research Areas:

Cancer is a genetic disease caused by the accumulation of genomic alterations. Our laboratory is interested in discovering genomic events that cause human cancers. We are aiming to translate these findings into early diagnosis and treatments for these deadly diseases. Our laboratory is engaged in:

(1) Molecular mechanisms of sarcoma progression;

(2) Molecular mechanisms of non-sarcoma cancer progression;

(3) Pan-cancer genomic analysis;

(4) Development of novel diagnostic tools and novel anti-cancer drugs.


Brief Biography:


1994.9-1999.7: Bachelor’s Degree in Medical Sciences, Shanghai Medical University 

2001.9-2007.1: Ph.D. Degree in Biochemistry and Molecular Biology, Fudan University  

Major Academic Appointments 

2017-present: Professor, Principal Investigator, Shanghai Institute of Nutrition and Health, CAS 

2015-2016: Professor, Principal Investigator, Shanghai Institutes for Biological Sciences/Joint Center for Translational Medicine (SIBS - Shanghai Changzheng Hospital), Institute for Translational Medicine (CAS-SMMU), Shanghai, China 

2007-2015: Postdoctoral Research Associate/Senior Research Staff Scientist/Instructor, Brigham and Women’s Hospital / Harvard Medical School 

1999-2007: Teaching and Research Assistant/Lecturer/Associate Professor, Shanghai Medical School, Fudan University 


Selected Publications: (*Corresponding Author)

  1. Li K#, Zheng X#, Tang H#, Zang Y#, Zeng C, Liu X, Shen Y, Pang Y, Wang S, Xie F, Lu X, Luo Y, Li Z, Bi W, Jia X, Huang T, Wei R, Huang K, Chen Z, Zhu Q, Zhang M, Li C, He Y, Gu Z, Xiao Y, Zhang X, Hu R, Fletcher J, Wang Y*. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer. J Exp Med. 2021;In press. doi: 10.1084/jem.20210151.
  2. Lu X#, Pang Y#, Cao H#, Liu X#, Tu L, Shen Y, Jia X, Lee JC, Wang Y*. Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Res. 2021;doi:10.1158/0008-5472.CAN-20-3580.
  3. Pang Y#, Xie F#, Cao H#, Wang C#, Zhu M, Liu X, Lu X, Huang T, Shen Y, Li K, Jia X, Li Z, Zheng X, Wang S, He Y, Wang L, Fletcher J*, Wang Y*. Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2019;116(45):22746-22753. (Direct submission)
    (highlighted by MedicalXpress, The Medical News, Genome Web, Science Codex, Asia-Pacific Biotech News)
  4. Liu X#, Li Z#, Wang Y*. Advances in targeted therapy and immunotherapy for pancreatic cancer. Adv Biology. 2020;1900236. doi: 10.1002/adbi.201900236.
  5. Zeng C#, Zhu L#, Jia X#, Pang Y#, Li Z#, Lu X, Xie F, Duan L, Wang Y*. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. Gastric Cancer. 2020;23(5):837-847.
  6. Li Z#, Shao C#, Liu X, Lu X, Jia X, Zheng X, Wang S, Zhu L, Li K, Pang Y, Xie F, Lu Y, Wang Y*. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis. 2020;41(1):44-55.
  7. Guan L, Li Z, Xie F, Pang Y, Zhang C, Tang H, Zhang H, Chen C, Zhan Y, Zhao T, Jiang H, Jia X, Wang Y*, Lu Y*. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer. J Exp Clin Cancer Res. 2020 Mar 23;39(1):53. doi:10.1186/s13046-020-01557-3.
  8. Wang YX, Marino-Enriquez A, Bennett RR, Zhu MJ, Shen YP, Eilers G, Lee JC, Fletcher BS, Gu ZZ, Fox EA, Antonescu CR, Fletcher CDM, Guo XQ, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics. (IF: 31.616) 2014;46(6):601-606.
    (highlighted by “Laboratory Investigation”, “Modern Pathology” and “BioWorld Today”, featured in “Cancer Discovery” Research Watch and selected as one of the most popular stories on nature.com)
  9. Serrano C#, Wang YX#, Marino-Enriquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GIST: Relevance of concomitant PI3K/AKT dysregulation. J Clin Oncol. (IF: 28.245) 2015;33(22):e93-96. (#Both authors contributed equally)
  10. Wang YX*, Fletcher JA*. Cell cycle and dystrophin dysregulation in GIST. Cell Cycle. 2015;14(17):2713-2714.
  11. Heinrich M, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors. Clin Sarcoma Res. 2019 Mar 5;9:3. doi:10.1186/s13569-019-0112-7. eCollection 2019.
  12. Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Marino-Enriquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. 2017;8:14674. doi: 10.1038/ncomms14674.
  13. Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual targeting of Insulin Receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res. 2017;77(18):5107-5117.
  14. Wang Y, Yan X, Mi S, Li Z, Wang Y, Zhu H, Sun X, Zhao B, Zhao C, Zou Y, Hu K, Ding X, Sun A, Ge J. Naoxintong attenuates ischaemia/reperfusion injury through inhibiting NLRP3 inflammasome activation. J Cell Mol Med. 2017;21(1):4-12.
  15. Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, Wang Y, Liu J, Liu Q. Discovery of N-(3-((1- Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide(CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors. J Med Chem. 2016;59(8):3964-3979.
  16. Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, Guo C, Wang Y, Dorfman C, Feldman HA, Frates MC, Song H, Jugo RH, Taguchi T, Hershman JM, Larsen PR, Huang SA. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014;370(14):1327-1334.
  17. Marino-Enriquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene. 2014;33(14):1872-1876.
  18. Lynn M, Wang Y, Slater J, Shah N, Conroy J, Ennis S, Morris T, Betts DR, Fletcher JA, O'Sullivan MJ. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagn Mol Pathol. 2013;22(2):76-84.
  19. Ravegnini G, Marino-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR,George S, Angelini S, Raut CP, Fletcher JA. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013;26(5):743-749.
  20. Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM,McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012;109(3):929-934.
  21. Wang YX, Qian LX, Dong YX, Yao LL, Gui YH, Zhong TP, Song HY. Bone Morphogenetic Protein-2 acts upstream of Myocyte-specific Enhancer Factor 2A to control embryonic cardiac contractility. Cardiovasc Res. 2007;74(2):290-303.
  22. Wang YX, Qian LX, Jiang Q, Dong YX, Gui YH, Zhong TP, Song HY. Myocyte-specific enhancer factor 2A is essential for zebrafish posterior somite development. Mech Dev. 2006;123(10):783-791.
  23. Wang YX, Qian LX, Yu Z, Jiang Q, Dong YX, Liu XF, Yang XY, Zhong TP, Song HY. Requirements of myocyte-specific enhancer factor 2A in zebrafish cardiac contractility. FEBS Lett. 2005;579(21):4843-4850.
  24. Wang Y, Zhong T, Qian L, Dong Y, Jiang Q, Tan L, Song H. Wortmannin induces zebrafish cardia bifida through a mechanism independent of phosphoinositide 3-kinase and myosin light chain kinase. Biochem Biophys Res Commun. 2005;331(1):303-308 (Cover Photo).
  25. Wang YX, Song HY. Developmental genetics of zebrafish cardiovascular systems. Section Genet Foreign Med Sci. 2004;27(4):220-223.
  26. Wang YX, Yang J, Ma CG, Yang XY, Song HY. VEGF121 cDNA gene transfer and expression in Vitro. Prog Biochem Biophys. 2003;30(4):612-616.
  27. Wang YX, Guan XQ, Yang J, Mo W, Song HY. Molecular Cloning, Expression and characterization of recombinant human vascular endothelial growth factor 121. Prog Biochem Biophys. 2002;29(3):444-448.